Search

Your search keyword '"Giannini, E"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Giannini, E" Remove constraint Author: "Giannini, E" Topic business.industry Remove constraint Topic: business.industry
39 results on '"Giannini, E"'

Search Results

1. Pattern of macrovascular invasion in hepatocellular carcinoma

2. Cognitive reserve as a useful variable to address robotic or conventional upper limb rehabilitation treatment after stroke: a multicentre study of the Fondazione Don Carlo Gnocchi

3. Breast Osteoblast-like Cells: A Reliable Early Marker for Bone Metastases From Breast Cancer

4. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

5. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study

6. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice

7. Metabolic disorders across hepatocellular carcinoma in Italy

8. Common issues in the management of patients in the waiting list and after liver transplantation

9. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome

10. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma

11. Development of a provisional core set of response measures for clinical trials of systemic sclerosis

12. Resminostat in advanced hepatocellular carcinoma (HCC) : Overall survival subgroup analysis of prognostic factors in the SHELTER trial

13. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population

14. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis

15. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

16. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

17. Years of life that could be saved from prevention of hepatocellular carcinoma

18. Surveillance for hepatocellular carcinoma with a 3-months interval in 'extremely high-risk' patients does not further improve survival

19. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

20. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter

21. Identification of clinical phenotypes and related survival in patients with large hccs

22. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

23. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

24. Platelets and hepatocellular cancer: Bridging the bench to the clinics

25. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study

26. AISF position paper on HCV in immunocompromised patients

27. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

28. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

29. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

30. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

31. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

32. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma

33. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

34. The evolutionary scenario of hepatocellular carcinoma in Italy: an update

35. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

36. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study

37. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients

38. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

39. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?

Catalog

Books, media, physical & digital resources